This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The authors stated that an epidemiological study was carried out at the Northwestern Memorial Hospital in Chicago, Illinois. The patients were followed during their hospital stay. No patient was lost to the follow-up assessment.
Analysis of effectiveness
All of the patients included in the initial study sample were accounted for in the analysis of effectiveness. The outcome measures used were the results of the analysis of the 200 specimens. More specifically, the percentage of patients positive to VRE in high-risk patients, patient hospitalised in the 2 years prior and patients with renal impairment.
Effectiveness results
The analysis of the 200 specimens revealed that 81 specimens were from high-risk units and 119 were from nonsurveillance units. Specimens from the latter (non-surveillance units) were collected from 94 patients, 5 of whom were found to be positive for VRE.
The routine surveillance programme of high-risk units identified 16 patients with VRE. Thus, 24% (5 of 21) of the patients with VRE were detected in non high-risk units. Of such patients, 3 (60%) had documented renal impairment, and all had at least one hospital admission in the prior 2 years.
Two of the 5 patients had never been seen at the authors' institution. A medical record review of VRE-negative patients revealed that 14% (n=12) had a history of renal impairment and 48% (n=41) were hospitalised in the past 2 years.
Overall, 10.6% (n=5) of the 47 patients who had been hospitalised in the past 2 years were colonised with VRE.
The hospital database revealed that 3.1% of 30,507 adult inpatients had a diagnosis of renal disease and 28.5% had been hospitalised in the previous 2 years.
Clinical conclusions
The results of the epidemiological study were used to calculate the probability values used in the decision model.
Modelling
A probabilistic decision model was constructed to compare the costs and benefits of the three screening strategies examined in the study. The model relied on a decision tree, which was the same for the three options. Patients entered the model at the time of hospital admission and were followed until they were discharged or died. Patients who were screened could test either positive or negative for VRE and then could be either colonised or not. Colonised patients could develop active VRE or remain carriers without active infection. Patients not colonised entered an embedded Markov model that transitioned patients among five health states at daily intervals. The five health states were no VRE, VRE colonisation, VRE infection, discharge, and death. Most of the transition probabilities were assigned a specific probability distribution. Some fixed (non-probabilistic) estimates were also used. The cycle length of the Markov model was 1 day but the time horizon was not reported (a short time horizon appears to have been considered).
